Not surprising Allergan is getting acquired now, says Mizuho managing director

AbbVie is buying Allergan for $188.24 per share, at a premium of almost 45 percent. Mizuho analyst Irina Koffler joins 'Squawk Box' to discuss the merger and Allergan CEO's track record.
03:30
Tue, Jun 25 20199:07 AM EST